共 103 条
- [1] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center [J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
- [6] [Anonymous], 2022, Melanoma: Cutaneous, Version 2.2022 - January 26, 2022. NCCN clinical practice guidelines in oncology
- [8] Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma - Case report and review [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01): : 42 - 45